Natera Says Signatera ctDNA Dynamics Predicted EFS in MIBC Trial
Natera said phase III VOLGA trial data presented at an ESMO Presidential Symposium showed 24-month event-free survival of 91% for persistently negative patients, 81% for patients whose ctDNA cleared before surgery and 55% for persistently positive patients.